Isomerase Therapeutics Ltd (Cambridge, UK), is delighted to announce that Neil Triggs was recently awarded his Lean Six Sigma (LSS) Black Belt. Six Sigma is a quality management methodology that seeks to continuously improve performance in manufacturing processes by using a data driven approach to identify, remove or minimise sources of variability. These approaches are well suited to the improvement and scale-up of biological processes, especially microbial fermentation and associated downstream processing.
Neil Triggs commented, “I am excited to have achieved this professional milestone after a significant period of study and examination. Generating value for customers is a priority for our technical teams and using LSS methodology forms a critical part of achieving this, particularly when handling complex chemical and biological processes. It supports effective decision making and systematically decreases the risks of process failure, particularly when scaling up”.
Matt Gregory, the CEO of Isomerase added, “This is a fantastic achievement for Neil and for the wider team. His leadership in the area of process development is a crucial part of our ambitious plans for growth. As we add to our capabilities with the opening of the new Bioprocess Facility where partners can advance their processes from lab-scale into a more industrial pilot-scale setting, embedding LSS methodologies will maximise successful outcomes in this facility and across our wider business.”
Our team is uniquely placed to assist partners with all aspects of microbial product and process discovery and development, including leading-edge synthetic biology, advanced strain improvement of microorganisms, genome sequence analysis, protein and peptide expression and isolation, fermentation and process development, DSP, compound isolation, analytical development and synthetic chemistry. In addition, Isomerase manages other aspects necessary for a commercially successful programme on behalf of partners, such as compound management and shipping and scaled manufacture.
We offer these capabilities underpinned by a portfolio of technology IP, and the combined experience of a core technical and leadership team with a substantive track record of successful product discovery and development collaborations with pharma and biotech companies.
We have supported numerous companies with a wide variety of microbial product and small molecule fermentation and synthetic chemistry projects, helping advance early stage concepts into valuable development programmes, and then continuing to support their progress to market with process improvement and scaled manufacture.
For more information please contact Isomerase via our contact page.